(NASDAQ:HSDT) shares are up 60% on 62,00 trades at $2.39

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference M2 Communications “ENP Newswire”

NEWTOWN, Pa. – Helius Medical Technologies, Inc. (Nasdaq: HSDT) (‘Helius’ or the ‘Company’), a neurotech company focused on neurological wellness, announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting taking place June 1-4 in National Harbor , Maryland .

‘We are excited to share our real-world findings on neuromodulation to improve MS patients’ ability to walk steadily and safely,’ said Antonella Favit-Van Pelt , MD, PhD, Helius Medical’s Chief Medical Officer. ‘Our findings show that neuromodulation stimulation is an effective rehabilitative intervention that is thought to engage mechanisms of upregulation and long-term potentiation, promoting neuroplasticity and improving gait functionality and mobility.’


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist